Prevention of osteoporosis after breast cancer

Maturitas

Volumn 64, Issue 1, 2009, Pages 4-8

  Reid, David M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Aromatase inhibitors; Bisphosphonates; Breast cancer; Denosumab; Guidelines; Osteoporosis

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; VITAMIN D;

BONE ATROPHY; BONE DENSITOMETRY; BONE TURNOVER; BREAST CANCER; CALCIUM INTAKE; CANCER CHEMOTHERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY MENOPAUSE; FRACTURE; FRAGILITY FRACTURE; HIGH RISK PATIENT; HORMONE INHIBITION; HUMAN; LIFESTYLE; OSTEOPOROSIS; REVIEW; VITAMIN INTAKE;

AROMATASE INHIBITORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CALCIUM, DIETARY; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MENOPAUSE, PREMATURE; MICRONUTRIENTS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 69349101459     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.07.008     Document Type: Review

References (21)

1. Annonymous. UK breast cancer incidence and mortality (2009). http://info.cancerresearchuk.org/cancerstats/types/breast/incidence [cited 14 July 2009]; Available from: http://info.cancerresearchuk.org/cancerstats/types/breast/incidence
2. Coleman R.E., Body J.J., Gralow J.R., and Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev 34 Suppl. 1 (2008) S31-42
3. Body J.J., Bergmann P., Boonen S., et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer-a consensus paper of the Belgian Bone Club. Osteoporos Int 18 November (11) (2007) 1439-1450
4. Hillner B.E., Ingle J.N., Berenson J.R., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer, American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18 6 (2000) 1378-1391
5. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 November 1 (21) (2003) 4042-4057
6. Smith M.R., Lee W.C., Brandman J., Wang Q., Botteman M., and Pashos C.L. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23 November 1 (31) (2005) 7897-7903
7. Molina J.R., Barton D.L., and Loprinzi C.L. Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf 28 5 (2005) 401-416
8. Melton III L.J., Crowson C.S., Malkasian G.D., and O'Fallon W.M. Fracture risk following bilateral oophorectomy. J Clin Epidemiol 49 October (10) (1996) 1111-1115
9. Powles T.J., Hickish T., Kanis J.A., Tidy A., and Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 January (1) (1996) 78-84
10. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., and Adams J.E. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21 August (8) (2006) 1215-1223
11. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., and Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 1 (2008) 45-53
12. Eastell R., Adams J.E., Coleman R.E., et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26 March 1 (7) (2008) 1051-1057
13. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 February 10 (5) (2007) 486-492
14. Coleman R.E., Banks L.M., Girgis S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8 February (2) (2007) 119-127
15. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 February 17 (9561) (2007) 559-570
16. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25 March 1 (7) (2007) 829-836
17. Bundred N.J., Campbell I.D., Davidson N., et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112 March 1 (5) (2008) 1001-1010
18. Brufsky A.M., Bosserman L.D., Caradonna R.R., et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9 May (2) (2009) 77-85
19. Lester J.E., Dodwell D., Purohit O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14 October 1 (19) (2008) 6336-6342
20. Ellis G.K., Bone H.G., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26 October 20 (30) (2008) 4875-4882
21. Reid D.M., Doughty J., Eastell R., et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34 (2008) S3-S18